IL6 and neoplasm: As shown in Figures 5G–M, co-injection with iBMSC significantly improved the metastasis ability of IMR32, which was demonstrated by the lower survival time and rate of mice, the higher tumor burden, lung weight, and IL6 expression in lung metastatic lesions.